.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Colorcon
Farmers Insurance
Argus Health
Teva
Dow
Daiichi Sankyo
Julphar
Healthtrust
Medtronic

Generated: December 12, 2017

DrugPatentWatch Database Preview

Loteprednol etabonate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for loteprednol etabonate and what is the scope of loteprednol etabonate patent protection?

Loteprednol etabonate
is the generic ingredient in three branded drugs marketed by Bausch And Lomb Inc, Bausch And Lomb, and Pharmos, and is included in six NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Loteprednol etabonate has twelve patent family members in ten countries.

There are nine drug master file entries for loteprednol etabonate. Three suppliers are listed for this compound.

Pharmacology for loteprednol etabonate

Medical Subject Heading (MeSH) Categories for loteprednol etabonate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bausch And LombZYLETloteprednol etabonate; tobramycinSUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombLOTEMAXloteprednol etabonateOINTMENT;OPHTHALMIC200738-001Apr 15, 2011RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And LombALREXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bausch And Lomb IncLOTEMAXloteprednol etabonateGEL;OPHTHALMIC202872-001Sep 28, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
PharmosLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020841-001Mar 9, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: loteprednol etabonate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb IncLOTEMAXloteprednol etabonateGEL;OPHTHALMIC202872-001Sep 28, 2012► Subscribe► Subscribe
PharmosLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020841-001Mar 9, 1998► Subscribe► Subscribe
PharmosLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020841-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombALREXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombLOTEMAXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombALREXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998► Subscribe► Subscribe
Bausch And LombALREXloteprednol etabonateSUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: loteprednol etabonate

Country Document Number Estimated Expiration
Canada2278802► Subscribe
European Patent Office0969812► Subscribe
Brazil9807117► Subscribe
South Korea20000070492► Subscribe
Australia6253398► Subscribe
Spain2205449► Subscribe
South Korea100472132► Subscribe
Germany69817788► Subscribe
Hong Kong1026363► Subscribe
Australia723024► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Queensland Health
Harvard Business School
Daiichi Sankyo
Merck
Cerilliant
Teva
Argus Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot